Matinas BioPharma Holdings (MTNB) Total Current Liabilities (2013 - 2026)
Matinas BioPharma Holdings (MTNB) posted quarterly Total Current Liabilities of $2.1 million for Q1 2026, down 5.72% year-over-year from $2.3 million in Q1 2025, and up 45.32% quarter-over-quarter from $1.5 million in Q4 2025.
Matinas BioPharma Holdings (MTNB) Total Current Liabilities (2013 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Total Current Liabilities for 14 consecutive years, with $2.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities fell 5.72% year-over-year to $2.1 million; the TTM figure through Mar 2026 stood at $2.1 million (down 5.72% YoY), while the FY2025 annual figure was $1.5 million, down 45.12% from the prior year.
- Total Current Liabilities improved to $2.1 million in Q1 2026 per MTNB's latest filing, from $1.5 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $5.4 million in Q2 2022 and bottomed at $1.5 million in Q4 2025.
- Historically, Total Current Liabilities has averaged $2.8 million across 5 years, with a median of $2.4 million in 2024.
- Annual changes were most pronounced in 2022 — Total Current Liabilities surged 69.65% — and 2023, when it plunged 51.9%.
- Matinas BioPharma Holdings' Total Current Liabilities stood at $4.3 million in 2022, then slumped by 38.82% to $2.6 million in 2023, then gained by 1.68% to $2.7 million in 2024, then sank by 45.12% to $1.5 million in 2025, then surged by 45.32% to $2.1 million in 2026.
- Business Quant data shows MTNB's Total Current Liabilities at $2.1 million in Q1 2026, $1.5 million in Q4 2025, and $1.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | Matinas BioPharma Holdings | 1.19 Mn | 375,426.61 | - | 1.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.35 Mn |
| Mar 31, 2026 | 2.13 Mn |
| Dec 31, 2025 | 1.46 Mn |
| Sep 30, 2025 | 1.50 Mn |
| Jun 30, 2025 | 1.78 Mn |
| Mar 31, 2025 | 2.26 Mn |
| Dec 31, 2024 | 2.67 Mn |
| Sep 30, 2024 | 2.12 Mn |
| Jun 30, 2024 | 2.39 Mn |
| Mar 31, 2024 | 2.00 Mn |
| Dec 31, 2023 | 2.62 Mn |
| Sep 30, 2023 | 3.23 Mn |
| Jun 30, 2023 | 2.59 Mn |
| Mar 31, 2023 | 1.90 Mn |
| Dec 31, 2022 | 4.29 Mn |
| Sep 30, 2022 | 4.90 Mn |
| Jun 30, 2022 | 5.38 Mn |
| Mar 31, 2022 | 3.77 Mn |
| Dec 31, 2021 | 4.35 Mn |
| Sep 30, 2021 | 4.10 Mn |